Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for MSL
1.62
-0.02 (-1.22%)
Apr 15 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.62 - 1.66
52 week 0.48 - 2.00
Open 1.62
Vol / Avg. 44,910.00/335,379.00
Mkt cap 84.11M
P/E     -
Div/yield     -
EPS -0.12
Shares 51.92M
Beta 0.01
Inst. own     -
Feb 14, 2014
Q1 2014 Envoy Capital Group Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -30.14% -6.09%
Operating margin -14.97% 19.40%
EBITD margin - 64.72%
Return on average assets -8.70% -1.93%
Return on average equity -16.91% -4.37%
Employees 6 -
CDP Score - -

Address

Suite 2110 100 Wellington St. West P.O. Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933725 (Phone)

Website links

Description

Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. In August 2013, the Company announced that the divestiture of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets to Okana Ventures Inc.

Officers and directors

David D. Guebert CPA Independent Chairman of the Board
Elie Farah President, Chief Executive Officer, Director
Ahmad Doroudian Executive Vice Chairman of the Board
Age: 50
Andrew Patient Chief Financial Officer
Ulrich Schoeberl Managing Director, European Operations
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director
Michael S. Cloutier Non-Executive Independent Director